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Background
Multiple sclerosis (MS) is a chronic, progressive, immune-mediated, neurodegenerative disease of the central nervous system, accumulating patient' s disability over time and causing significant human and economic burden. Approximately 80-90% of the incident MS cases are relapsing-remitting MS (RRMS) characterised by phases of remission and relapse. Important goals of the disease-modifying drug treatment (DMT) in MS are to arrest or slow the accumulation of disability (measured on the Expanded Disability Status Scale, EDSS) and delay progression of the disease to secondary progressive multiple sclerosis (SPMS). Based on the literature and Finnish register data, there is an economic and clinical unmet need for more safe and effective RRMS treatments. Currently widely used injectable DMTs impose limitations in tolerability and safety. Adverse events (AE) including e.g. injection-site or skin reactions, myalgia, fever, influenza-like symptoms, asthenia, chills and neutralizing antibodies are common and they often prevent patients from continuing DMTs. Teriflunomide (Aubagio® 14mg) is oral once daily administered immunomodulatory DMT indicated for adult RRMS patients. It is effective and well-tolerated with a manageable safety profile. Recently, a basic reimbursement for confirmed RRMS in adults was granted for Aubagio® in Finland. No Finnish cost-effectiveness analysis of MS DMTs has been published.
Objective
Evaluate the cost-utility of teriflunomide (Aubagio® 14mg) and other first-line DMTs glatiramer acetate (GA: Copaxone® 20mg), interferon-β-1a (IFNβ-1a: intramuscular (IM) Avonex® 30mcg, subcutaneous (SC) Rebif® 44mcg) or interferon-β-1b (IFNβ-1b: Betaferon® 250mcg), compared to best supportive care (BSC) in Finnish RRMS-patients.
Methods
Key study methods included a Finnish register study and Markov cohort modelling.
Decision analytic modelling
During the modelled 50-year time horizon, patients could stay in, or progress to another Expanded Disability Status Scale (EDSS) state, experience relapse (with/ without hospitalisation), adverse events (AE) or death (EDSS 10, absorbing state). A simplified presentation of the Markov model is given in Figure 1 . The CEEF shows the ICERs of non-dominated treatments. The EVPI per patient demonstrates the maximum monetary value of parameter uncertainty that can be resolved by acquiring perfect evidence for the model parameters or alternatively the expected monetary consequences related to wrong treatment acquisition decision. Quality of life estimates, which were derived from literature, and Finnish costs (health-care costs in year 2013 value; drug costs without VAT in Aug/2014 value) were associated with EDSS, relapses, and AEs. Indirect treatment comparison informed treatment effects.
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Sensitivity analysis
Caregiver disutility and Finnish productivity losses and informal care costs were included in sensitivity analysis (societal perspective).
Results
Expected lifetime healthcare (base case) costs, societal costs and QALYs per patient were given in Local register data EDSS-related standardised mortality ratios (SMR) and RRMS-progression matrix were analysed from a Finnish MS-register (1359 patients from Tampere, Vaasa, Seinäjoki regions). Other health risks were based on literature. Cohort characteristics were estimated from a subgroup of the Finnish register patients who fulfilled the indication of modelled treatment comparators (713 patients applicable for 1st line MS-DMT: clinically confirmed RRMS, age, gender and EDSS 0-6.5 at first DMT initiation).
Health economic analysis
The following outcomes were considered in the base-case analysis: direct health care costs, quality-adjusted life-years (QALY) based on EQ-5D, incremental costeffectiveness ratios (ICER, the primary outcome), cost-effectiveness efficiency frontier (CEEF), and expected value of perfect information per patient (EVPI). Costs and QALYs were discounted with 3% per year.
From the payer or societal perspectives and over a 50 years' time horizon, teriflunomide 14 mg was dominant (less costly and more effective) compared to other first-line DMTs. Furthermore, teriflunomide 14 mg was cost-effective when compared to BSC with an ICER of 8,572 €/QALY gained for the payer perspective and dominant for the societal perspective. Figure 2 shows the CEEF from the payer perspective. The CEEF includes teriflunomide 14 mg and BSC.
In the comparison of teriflunomide (Aubagio® 14mg) and IFNβ-1a-SC (Rebif® 44mcg), teriflunomide had 80% [per-patient EVPI €248], 98% [per-patient EVPI €17], and 100% [per-patient EVPI €0] cost-effectiveness probability at a willingness-to-pay of €0, €10,000, and €20,000 per additional QALY, respectively.
Conclusion
Cost-effectiveness analyses of first-line DMTs projected that teriflunomide 14 mg would provide the best value for money with both the lowest cost and highest QALY gained. 
